Boehringer Ingelheim Corporation Release: Pharmaco-Invasive Strategy Including Metalyse® Delivers Comparable Clinical Outcomes to Primary PCI for STEMI Patients Who Could Not Undergo Primary PCI Within One Hour From First Medical Contact

INGELHEIM, Germany--(BUSINESS WIRE)-- New data presented at the American College of Cardiology 62nd Annual Scientific Sessions and Expo demonstrate that patients with ST elevation acute myocardial infarction (STEMI), who cannot undergo primary percutaneous intervention (PCI) in a catheterization lab within 60 minutes of first medical contact, have similar clinical outcomes from early fibrinolysis with Metalyse® (tenecteplase, TNK-tPA) followed by timely angiography (pharmaco-invasive strategy), compared to primary PCI.1